|
1
|
Lim IIP, Bondoc AJ, Geller JI and Tiao GM:
Hepatoblastoma-the evolution of biology, surgery, and
transplantation. Children (Basel). 6:12018.PubMed/NCBI
|
|
2
|
Aronson DC, Czauderna P, Maibach R,
Perilongo G and Morland B: The treatment of hepatoblastoma: Its
evolution and the current status as per the SIOPEL trials. J Indian
Assoc Pediatr Surg. 19:201–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zsiros J, Brugieres L, Brock P, Roebuck D,
Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB,
et al: Dose-dense cisplatin-based chemotherapy and surgery for
children with high-risk hepatoblastoma (SIOPEL-4): A prospective,
single-arm, feasibility study. Lancet Oncol. 14:834–842. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schimmer AD: Inhibitor of apoptosis
proteins: Translating basic knowledge into clinical practice.
Cancer Res. 64:7183–7190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finlay D, Teriete P, Vamos M, Cosford NDP
and Vuori K: Inducing death in tumor cells: Roles of the inhibitor
of apoptosis proteins. F1000Res. 6:5872017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benetatos CA, Mitsuuchi Y, Burns JM,
Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, LaPorte MG,
Rippin SR, et al: Birinapant (TL32711), a bivalent SMAC mimetic,
targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB
activation, and is active in patient-derived xenograft models. Mol
Cancer Ther. 13:867–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dynek JN and Vucic D: Antagonists of IAP
proteins as cancer therapeutics. Cancer Lett. 332:206–214. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nachmias B, Ashhab Y and Ben-Yehuda D: The
inhibitor of apoptosis protein family (IAPs): An emerging
therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Camp JG, Sekine K, Gerber T,
Loeffler-Wirth H, Binder H, Gac M, Kanton S, Kageyama J, Damm G,
Seehofer D, et al: Multilineage communication regulates human liver
bud development from pluripotency. Nature. 546:533–538. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
11
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amaravadi RK, Schilder RJ, Martin LP,
Levin M, Graham MA, Weng DE and Adjei AA: A phase I study of the
SMAC-mimetic birinapant in adults with refractory solid tumors or
lymphoma. Mol Cancer Ther. 14:2569–2575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noonan AM, Bunch KP, Chen JQ, Herrmann MA,
Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, et
al: Pharmacodynamic markers and clinical results from the phase 2
study of the SMAC mimetic birinapant in women with relapsed
platinum-resistant or -refractory epithelial ovarian cancer.
Cancer. 122:588–597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allensworth JL, Sauer SJ, Lyerly HK, Morse
MA and Devi GR: Smac mimetic Birinapant induces apoptosis and
enhances TRAIL potency in inflammatory breast cancer cells in an
IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res
Treat. 137:359–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stucchi G, Battevi N, Cairoli S and
Consonni D: The prevalence of musculoskeletal disorders in the
retail sector: An Italian cross sectional study on 3,380 workers.
Med Lav. 107:251–262. 2016.PubMed/NCBI
|
|
17
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
LaCasse EC, Baird S, Korneluk RG and
MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging
role in cancer. Oncogene. 17:3247–3259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wallace C and Unger S: A matter of life
and death. Commun Int. 26:341999.
|
|
20
|
Krajewska M, Krajewski S, Banares S, Huang
X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A,
Peehl D, et al: Elevated expression of inhibitor of apoptosis
proteins in prostate cancer. Clin Cancer Res. 9:4914–4925.
2003.PubMed/NCBI
|
|
21
|
Tanimoto T, Tsuda H, Imazeki N, Ohno Y,
Imoto I, Inazawa J and Matsubara O: Nuclear expression of cIAP-1,
an apoptosis inhibiting protein, predicts lymph node metastasis and
poor patient prognosis in head and neck squamous cell carcinomas.
Cancer Lett. 224:141–151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakagawa Y, Abe S, Kurata M, Hasegawa M,
Yamamoto K, Inoue M, Takemura T, Suzuki K and Kitagawa M: IAP
family protein expression correlates with poor outcome of multiple
myeloma patients in association with chemotherapy-induced
overexpression of multidrug resistance genes. Am J Hematol.
81:824–831. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC,
Goan YG and Lee H: cIAP2 upregulated by E6 oncoprotein via
epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT
pathway confers resistance to cisplatin in human papillomavirus
16/18-infected lung cancer. Clin Cancer Res. 16:5200–5210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miura K, Karasawa H and Sasaki I: cIAP2 as
a therapeutic target in colorectal cancer and other malignancies.
Expert Opin Ther Targets. 13:1333–1345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagata M, Nakayama H, Tanaka T, Yoshida R,
Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A and
Shinohara M: Overexpression of cIAP2 contributes to 5-FU resistance
and a poor prognosis in oral squamous cell carcinoma. Br J Cancer.
105:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lopes RB, Gangeswaran R, McNeish IA, Wang
Y and Lemoine NR: Expression of the IAP protein family is
dysregulated in pancreatic cancer cells and is important for
resistance to chemotherapy. Int J Cancer. 120:2344–2352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee SK, Kim SB, Kim JS, Moon CH, Han MS,
Lee BJ, Chung DK, Min YJ, Park JH, Choi DH, et al: Butyrate
response factor 1 enhances cisplatin sensitivity in human head and
neck squamous cell carcinoma cell lines. Int J Cancer. 117:32–40.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ebert G, Lopaticki S, O'Neill MT, Steel
RWJ, Doerflinger M, Rajasekaran P, Yang ASP, Erickson S, Ioannidis
L, Arandjelovic P, et al: Targeting the extrinsic pathway of
hepatocyte apoptosis promotes clearance of plasmodium liver
infection. Cell Rep. 30:4343–4354.e4. 2020. View Article : Google Scholar : PubMed/NCBI
|
